Age, years
|
53 (45–57)
|
50 (44–58)
|
0.92
|
Male gender (%)
|
11 (61)
|
11 (69)
|
0.70
|
SAPS 2 score
|
35 (27–54)
|
35 (29–50)
|
0.98
|
BMI, kg/m2
|
29.1 (26.1–31.9)
|
34.5 (26.10–35.8)
|
0.40
|
Between ICU admission and ECMO weaning
| | | |
History of previous lung disease
|
0 (0)
|
1 (6)
|
0.47
|
Chest CT-scan upon ICU admission
| | | |
Pulmonary embolism
|
1 (6)
|
2 (13)
|
0.59
|
Lung parenchyma affected, %
|
68 (50–90)a
|
75 (50–75)b
|
0.50
|
Corticosteroids during ICU stay
| | | |
Dexamethasone
|
11 (61)
|
9 (56)
|
> 0.99
|
Hydrocortisone/Fludrocortisone
|
8 (44)
|
4 (33)
|
0.30
|
Methylprednisolone pulse therapy
|
2 (11)
|
1 (6)
|
> 0.99
|
Renal replacement therapy
|
7 (39)
|
5 (31)
|
0.73
|
Ventilator-associated pneumonia
|
17 (94)
|
10 (63)
|
0.030
|
Major bleedingc
|
13 (72)
|
4 (25)
|
0.015
|
ECMO support duration, days
|
24 (16–43)
|
10 (7–14)
|
< 0.001
|
At time of ECMO weaning trial
| | | |
Ventilator settings during ECMO weaning
| | | |
Tidal volume, mL
|
345
(308–396)
|
400 (320–442)
|
0.10
|
Tidal Volume, mL/kg PBW
|
5.6 (4.8–5.9)
|
5.8 (5.5–6.1)
|
0.20
|
Respiratory rate, breaths/min
|
34 (30–38)
|
29 (26–32)
|
0.002
|
Plateau pressure, cmH2O
|
31 (29–34)
|
25 (22–26)
|
< 0.001
|
Driving pressure, cmH2O
|
24 (22–27)
|
13 (12–16)
|
< 0.001
|
RS compliance, mL/cmH2O
|
14 (12–17)
|
27 (22–35)
|
< 0.001
|
PEEP, cmH2O
|
5 (5–8)
|
10 (7–12)
|
0.003
|
Arterial blood gases during weaning
| | | |
pH
|
7.35 (7.27–7.38)
|
7.42 (7.36–7.44)
|
0.008
|
PaCO2, mmHg
|
47 (42–55)
|
41 (37–44)
|
0.001
|
PaO2, mmHg
|
82 (71–96)
|
84 (76–104)
|
0.37
|
Arterial lactate levels, mmol/L
|
0.9 (0.6–1.2)
|
1.1 (0.9–1.4)
|
0.10
|
HCO3−, mmol/L
|
27 (24–29)
|
27 (23–29)
|
0.90
|
PaO2/FiO2 ratio, mmHg
|
166 (145–202)
|
200 (156–254)
|
0.25
|
FiO2
|
50 (40–60)
|
50 (40–50)
|
0.29
|
BAL fluid cytological analysisd
| | | |
Total cell counts; 103/mL
|
474 (240–772)
|
500 (259–873)
|
0.90
|
Macrophages, %
|
27 (12–48)
|
75 (18–89)
|
0.15
|
Neutrophils, %
|
50 (27–71)
|
18 (5–50)
|
0.07
|
Lymphocytes, %
|
9 (2–17)
|
4 (3–35)
|
0.67
|
Eosinophils, %
|
1 (0–3)
|
0 (0–2)
|
0.24
|
Chest CT-scan at time of weaninge
| | | |
Reticular pattern
|
3 (21)
|
1 (8)
|
0.60
|
Ground glass opacity
|
11 (78)
|
12 (100)
|
0.13
|
Alveolar condensation
|
12 (86)
|
9 (75)
|
0.53
|
Traction bronchiectasis
|
12 (86)
|
5 (12)
|
0.038
|
Tracheal distorsion
|
1 (7)
|
0 (0)
|
> 0.99
|
Scissural distortion
|
4 (29)
|
2 (16)
|
0.59
|
After ECMO withdrawal
| | | |
MV with non-protective settingsf, days
|
6 (4–10)
|
1 (0–2)
|
< 0.0001
|
Rescue therapy after weaning
| | | |
Prone positioning
|
9 (50)
|
1 (6)
|
0.008
|
Inhaled nitric oxide
|
4 (22)
|
1 (6)
|
0.34
|
Methylprednisolone pulse therapy
|
1 (5)
|
0 (0)
|
–
|
RS mechanics on the day of MV weaning
| | | |
Pressure support level, cm H2O
|
11 (8–14)
|
10 (8–13)
|
0.60
|
Tidal volume, mL
|
520 (411–609)
|
471 (397–622)
|
0.75
|
Tidal volume, mL/kg PBW
|
7.2 (6.3–8.4)
|
7.0 (5.9–8.7)
|
0.98
|
Complianceg, mL/cmH2O
|
44.7 (35.2–62.4)
|
48.9 (34.1–77.8)
|
0.78
|
Total MV duration, days
|
55 (38–86)h
|
21 (14–31)
|
0.0002
|
MV duration after ECMO weaning, days
|
26 (16–36)h
|
5 (3–12)
|
< 0.0001
|
ICU length of stay, days
|
55 (40–91)h
|
27 (19–32)
|
< 0.0001
|
In-ICU mortality
|
2 (13)h
|
1 (6)
|
0.60
|